View Author
patient hbeag hepatitis study treatment hbsag hbeag loss hepatitis b level tenofovir virus therapy baseline hbv dna response diabetes mellitus tenofovir df hbsag loss analysis gilead sciences diabetes university adefovir dipivoxil liver adefovir peg-ifn mellitu group hepatitis b virus hbeag ϩ patients bcp mutants 32 weeks hbeag-positive mutant dipivoxil infection hepatology serum genotype science hbv dna level week 32 week 144 hepatocellular carcinoma lecture fees hbv dna levels resistance gastroenterology gilead value score hbeag-positive patients hbv genotype hbv infection table wt virus follow-up lamivudine milliliter antigen hepatitis c grant support presence disease clearance consulting event factor suppression change bristol myers squibb hbsag negativity 400 copies limit safety erasmus university alanine brosi aminotransferase england journal
6 Most Recent Publications
|
Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B
(Article)
Sonneveld, M.J. Rijckborst, V. Zeuzem, S. Heathcote, E.J. Simon, K. Senturk, H. Pas, S.D. Hansen, B.E. Janssen, H.L.A. |
2012-07-01
|
|
Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: Relation to response and HBV genotype
(Article)
Sonneveld, M.J. Rijckborst, V. Janssen, H.L.A. Cakaloglu, Y. Simon, K. Heathcote, E.J. Tabak, F. Mach, T. Boucher, C.A.B. Hansen, B.E. Zeuzem, S. |
2012-01-30
|
|
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B
(Article)
Heathcote, E.J. Marcellin, P. Manns, M. Kotzev, I. Tchernev, K. Buggisch, P. Weilert, F. Kurdas, O.O. Shiffman, M.L. Trinh, H. Gurel, S. Snow-Lampart, A. Buti, M. Borroto-Esoda, K. Mondou, E. Anderson, J. Sorbel, J. Rousseau, F. Gane, E. Man, R.A. de Krastev, Z. Germanidis, G. Lee, S.S. Flisiak, R. Kaita, K. |
2011-01-01
|
|
Early hbeag loss during peginterferon α-2b therapy predicts HBsAg loss: Results of a long-term follow-up study in chronic hepatitis B patients
(Article)
Buster, E.H.C.J. Flink, H.J. Hansen, B.E. Janssen, H.L.A. Simsek, H. Heathcote, E.J. Sharmila, S. Kitis, G.E. Gerken, G. Buti, M. Vries, R.A. de Verhey, E. |
2009-10-01
|
|
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B
(Article)
Marcellin, P. Heathcote, E.J. Manns, M.P. Kotzev, I. Tchernev, K. Buggisch, P. Weilert, F. Kurdas, O.O. Shiffman, M.L. Trinh, H. Washington, M.K. Sorbel, J. Buti, M. Anderson, J. Snow-Lampart, A. Mondou, E. Quinn, J. Rousseau, M.F. Gane, E. Man, R.A. de Krastev, Z. Germanidis, G. Lee, S.S. Flisiak, R. Kaita, K. |
2008-12-04
|
|
Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus
(Article)
Veldt, B.J. Chen, W. Schalm, S.W. Janssen, H.L.A. Heathcote, E.J. Wedemeyer, H. Reichen, J. Hofmann, W.P. Knegt, R.J. de Zeuzem, S. Manns, M.P. Hansen, B.E. |
2008-06-01
|
